Inspira Technologies OXY B.H.N. Ltd. has announced a strategic shift to accelerate the global commercial rollout of its FDA-cleared ART100 system. Following successful clinical implementations in the U.S., the company is actively engaged in discussions with governmental health departments and private organizations to expand the system's reach. This expansion aligns with the growing demand for alternatives to mechanical ventilation and positions Inspira as a key player in scalable respiratory solutions. The company is prioritizing near-term revenue activities while continuing to support its innovation pipeline, including the development of the next-generation INSPIRA™ ART500 and the HYLA™ blood sensor. Deliveries of the ART100 system are expected to begin in the second half of 2025, contingent on the finalization of commercial and legal terms.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。